Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. [electronic resource]
Producer: 20020528Description: 383-93 p. digitalISSN:- 1078-0432
- ATP Binding Cassette Transporter, Subfamily B, Member 1 -- metabolism
- Adult
- Aged
- Antibiotics, Antineoplastic -- pharmacology
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Disease Progression
- Disease-Free Survival
- Doxorubicin -- therapeutic use
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Middle Aged
- Piperidines -- pharmacokinetics
- Pyridines -- pharmacokinetics
- Sarcoma -- drug therapy
- Soft Tissue Neoplasms -- drug therapy
- Time Factors
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.